Summary by Moomoo AI
Panbela Therapeutics, a clinical-stage biopharmaceutical company, filed a prospectus supplement on May 15, 2024, to update information in its April 15, 2024 prospectus. The supplement includes the company's Quarterly Report filed with the SEC on the same date. The update relates to the resale of 255,600 shares of common stock by selling securityholders. Panbela's common stock is quoted on the OTCQB under the symbol 'PBLA,' with the last reported sales price being $0.4408 per share as of May 14, 2024. The supplement and the original prospectus must be read together, with the supplement taking precedence in case of inconsistencies. Panbela's financial statements reveal a net loss of $7.1 million for the quarter ended March 31, 2024, with a decrease in cash and cash equivalents from $2.578 million to...Show More
